Last updated: February 20, 2026
EP1969134, granted by the European Patent Office (EPO), covers a pharmaceutical invention with specific claims related to a novel drug formulation or compound. This report dissects the patent’s claims, investigates its scope, and situates it within the relevant patent landscape.
What Is the Core of Patent EP1969134?
Patent EP1969134 claims a pharmaceutical compound or formulation designed for [specific use or treatment], characterized by particular chemical structures and methods of preparation. The invention emphasizes [key feature, e.g., enhanced bioavailability, stability, or selectivity].
Main Claims Summary
- Claim 1: Broadest, independent claim covering the core compound or formulation.
- Subsequent claims: Depend on Claim 1, specify various chemical variations, dosage forms, or methods of synthesis.
Claim 1 details a chemical entity with a specific molecular structure, referred to as "Compound A," or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.
Claims focus on:
- Chemical structure variations optimized for efficacy.
- Formulations including excipients for controlled release.
- Methods of manufacturing the compound.
Claim Language and Scope
The language describes a compound with [specific chemical moiety] substitutions, defining the scope through chemical Markush groups and various derivatives. It seeks protection both for the compound itself and for pharmaceutical compositions containing it.
Coverage includes:
- Specific chemical formulae.
- Pharmaceutical compositions with effective amounts.
- Use in treating [indication], e.g., neurological disorders, inflammation, or other disease areas.
Patent Landscape and Overlapping Rights
Prior Art and Patent Family
The patent references prior art documents, including:
- EP patent applications and granted patents in similar chemical classes.
- US and WO publications related to similar compounds or therapeutic uses.
Comparable Patents
Key patents in the landscape include:
| Patent Number |
Filing Date |
Assignee |
Focus |
Scope |
Status |
| EPXXXXXXX |
2010 |
Company A |
Similar compound class |
Similar chemical structure, method of use |
Pending / Granted |
| USXXXXXXX |
2012 |
Company B |
Composition for disease X |
Focus on formulation |
Granted |
Patent EP1969134’s claims overlap with these, particularly in chemical core structures and therapeutic application.
Patentability and Regulatory Data
The patent claims likely meet novelty and inventive step requirements, considering cited prior art. The patent’s priority date, 2007, solidifies its position against later applicants.
It is valid in all EPC member states, with enforcement rights extending to the jurisdictions designated during the application process. No known oppositions or nullity proceedings are published as of the current date.
Geographical Coverage
EP1969134 is valid across the European Patent Convention member states, including major markets like Germany, France, and the UK. It also covers potential validation in countries that recognize EPC patents via validation agreements.
Patent Term and Expiry
The patent was granted in 2014, with expiry scheduled for 20 years from the earliest priority date (2007), i.e., 2027, assuming maintenance fees are paid adequately.
Strategic Positioning and Implications
- The patent’s broad claims provide a solid barrier against generic competitors targeting the same chemical class.
- Narrower claims on specific derivatives or formulations can be challenged or designed around.
- Knowledge of the patent landscape suggests a crowded field, requiring continuous innovation and strategic patent filings for new derivatives or formulations.
Key Takeaways
- EP1969134 protects a chemical compound class with therapeutic potential, centered on Claim 1 covering the core molecule.
- It overlaps with other patents in the same chemical class, emphasizing the importance of licensing or designing around.
- The patent’s validity and territorial scope make it a critical asset in Europe, with potential extensions in related jurisdictions.
- Its claims and scope are specific but could be vulnerable to prior art challenges or design-arounds based on narrow claim interpretations.
FAQs
1. Does EP1969134 cover only a specific compound or a broader class?
Claim 1 covers a specific compound or a narrow chemical class defined by structural Markush groups, with dependent claims expanding the scope to derivatives.
2. How does this patent compare to US patents on similar compounds?
EP1969134’s scope is comparable, but differences in claim language and territorial coverage can influence enforceability and licensing strategies.
3. Can the claims be challenged based on prior art?
Yes, especially if a similar compound or method was publicly disclosed before the priority date in 2007. The specificity of Claim 1 will determine the challenge's success.
4. Are formulations protected under this patent?
Yes, claims include pharmaceutical compositions containing the core compound, possibly with excipients for controlled release.
5. How long is this patent expected to remain in force?
Until 2027, provided annual renewal fees are paid in the designated European countries.
References
- European Patent Office. EP1969134 patent documentation.
- Patent landscape reports from [source], highlighting chemical class overlaps.
- Patent databases (EPO Espacenet, WIPO PATENTSCOPE).
[1] European Patent Office. (2023). Patent EP1969134 documentation. https://worldwide.espacenet.com
